Meta-analysis of efficacy and safety of congiogenesis inhibitors combined with chemotherapy in the treatment of patients with recurrent ovarian cancer
LI Ruo-bin
OUYANG Yuan
PING Wen-ping
ZHANG Qi
WANG Xiao-yu
Abstract：Objective To study the efficacy and safety of angiogenesis inhibitors combined with chemotherapy in treatment of recurrent ovarian cancer.Methods The PubMed,Embase,The Cochrane Library,CBM,CNKI,VIP and Wan Fang Databases were electronically searched for publications from inception to January 2016 to collect randomized controlled trials (RCTs) about the efficacy and safety of angiogenesis inhibitors combined with chemotherapy in the treatment of patients with recurrent ovarian cancer and compared with routine chemotherapy.Literature data screening and bias risk assessing were independently executed by two reviewers.Meta-analysis was performed by Rev Man 5.3 software.Results Overall,6 RCTs involving 2028 recurrent ovarian cancer patients were included.The results were as follows:(1) OS and PFS for the angiogenesis inhibitors group was superior to the control group,respectively [HR=0.87,95％CI (0.76,0.99),P ＜ 0.05] and [HR=0.56,95 ％ CI (0.47,0.67),P ＜ 0.05].(2) There was no significant difference between two group in the total grade 3 or higher (P ＞ 0.05).Grade 3 or higher hypertension and proteinuria occurred more frequently in the anti-VEGF group(P ＜ 0.05).Grade 3 or higher proteinuria and grade 2 or lower diarrhea and nausea occurred more frequently in the anti-VEGFR group(P ＜ 0.05).More incidences of generalized edema occurred in the antiANG group (P ＜ 0.05).Conclusion Angiogenesis inhibitors combined with chemotherapy can improve OS and PFS.The total incidence of adverse reactions is similar to that of the routine chemotherapy group.The type and severity of adverse reactions are different in different mechanisms of angiogenesis inhibitors.
Keywords：angiogenesis inhibitorrecurrent ovarian cancersystematic reviewMeta-analysisrandomized controlled trials
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 288-292 )